Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin

European Journal of Endocrinology

Volumn 170, Issue 3, 2014, Pages 451-459

  Jensterle Sever, Mojca ^a   Kocjan, Tomaz ^a   Pfeifer, Marija ^a   Kravos, Nika Aleksandra ^a   Janez, Andrej ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; LIRAGLUTIDE; METFORMIN;

ADD ON THERAPY; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INJECTION SITE RASH; INSOMNIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; MONOTHERAPY; NAUSEA; OBESITY; OPEN STUDY; OVARY POLYCYSTIC DISEASE; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; WAIST CIRCUMFERENCE; WEIGHT CHANGE; WEIGHT REDUCTION;

ADULT; BODY WEIGHT; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; METFORMIN; OBESITY; RECEPTORS, GLUCAGON; WAIST CIRCUMFERENCE; WEIGHT LOSS;

EID: 84896270054     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0797     Document Type: Article

References (32)

1. Palomba S, Falbo A, Zullo F & Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocrine Reviews 2009 30 1-50. (doi:10.1210/er.2008-0030)
2. Diamanti-Kandarakis E, Christakou CD, Kandaraki E & Economou FN. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. European Journal of Endocrinology 2010 162 193-212. (doi:10.1530/EJE-09-0733)
3. Dunaif A. Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome - a reappraisal. Nature Clinical Practice. Endocrinology & Metabolism 2008 4 272-283. (doi:10.1038/ncpendmet0787)
4. Pasquali R & Gambineri A. Targeting insulin sensitivity in the treatment of polycystic ovary syndrome. Expert Opinion on Therapeutic Targets 2009 13 1205-1226. (doi:10.1517/14728220903190699)
5. Panidis D, Tziomalos K, Papadakis E, Kandaraki EA & Katsikis I. The guidelines issued by the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine regarding the induction of ovulation with metformin in patients with the polycystic ovary syndrome potentially require reconsideration. Hormones 2013 12 192-200.
6. Lord JM, Flight IHK & Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003 327 951. (doi:10.1136/bmj.327.7421.951)
7. Harborne LR, Sattar N, Norman JE & Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. Journal of Clinical Endocrinology and Metabolism 2005 90 4593-4598. (doi:10.1210/jc.2004-2283)
8. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK & Elahi D. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. Journal of Clinical Endocrinology and Metabolism 2009 94 1843-1852. (doi:10.1210/jc.2008-1296)
9. Woods SC & D'Alessio DA. Central control of body weight and appetite. Journal of Clinical Endocrinology and Metabolism 2008 93 (11 Suppl 1) 37-50. (doi:10.1210/jc.2008-1630)
10. Vilsbøll T, Christensen M, Junker AE, Knop FK & Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomized controlled trials. BMJ 2012 344 d7771. (doi:10.1136/bmj.d7771)
11. Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D & Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2008 93 2670-2678. (doi:10.1210/jc. 2008-0115)
12. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L & LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009 374 39-47. (doi:10.1016/S0140-6736(09)60659-0)
13. Zawadzki JK & Dunaif A. Diagnostic criteria for polycystic ovary syndrome. In Polycystic Ovary Syndrome, pp 377-384. Eds A Dunaif, F Haseltine & GR Merriam, Boston: Blackwell Scientific Publications, 1992.
14. Azziz R & Zacur HA. 21-Hydroxylase deficiency in female hyperandrogenism: screening and diagnosis. Journal of Clinical Endocrinology and Metabolism 1989 69 577-584. (doi:10.1210/jcem-69-3-577)
15. Ryo M, Maeda K, Onda T, Katashima M, Okumiya A, Nihida M, Yamaguchi T, Funahashi T, Matsuzawa Y, Nakamura T et al. A new simple method for the measurement of visceral fat accumulation by bioelectrical impedance. Diabetes Care 2005 28 451-453. (doi:10.2337/diacare.28.2.451)
16. DiBrezzo R, Fort IL & Brown B. Relationships among strength, endurance, weight and body fat during three phases of the menstrual cycle. Journal of Sports Medicine and Physical Fitness 1991 31 89-94.
17. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003 26 3160-3167. (doi:10.2337/diacare.26. 12.3331)
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419. (doi:10.1007/BF00280883)
19. Hedblad B, Nilsson P, Janzon L & Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabetic Medicine 2000 17 299-307. (doi:10.1046/j.1464-5491.2000.00280.x)
20. Nicklas BJ, Penninx BW, Ryan AS, Berman DM, Lynch NA & Dennis KE. Visceral adipose tissue cutoffs associated with metabolic risk factors for coronary heart disease in women. Diabetes Care 2003 26 1413-1420. (doi:10.2337/diacare.26.5.1413)
21. Holst JJ & Deacon CF. Is there a place for incretin therapies in obesity and prediabetes? Trends in Endocrinology and Metabolism 2013 24 145-152. (doi:10.1016/j.tem.2013.01.004)
22. Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K & Trautmann M. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without prediabetes. Diabetes Care 2010 33 1173-1175. (doi:10.2337/dc09-1203)
23. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME & NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomized, doubleblind, placebo-controlled study. Lancet 2009 374 1606-1616. (doi:10.1016/S0140-6736(09) 61375-1)
24. Spanos N, Tziomalos K, Macut D, Koiou E, Kandaraki EA, Delkos D, Tsourdi E & Panidis D. Adipokines, insulin resistance and hyperandrogenemia in obese patients with polycystic ovary syndrome: cross-sectional correlations and the effects of weight loss. Obesity Facts 2012 5 495-504. (doi:10.1159/000341579)
25. Jayagopal V, Kilpatrick ES, Holding S, Jennings PE & Atkin SL. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. Journal of Clinical Endocrinology and Metabolism 2005 90 729-733. (doi:10.1210/jc.2004-0176)
26. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M & Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clinical Science 2012 122 253-270. (doi:10.1042/CS20110386)
27. Maida A, Lamont BJ, Cao X & Drucker DJ. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia 2011 54 339-349. (doi:10.1007/s00125-010-1937-z)
28. Mannucci E, Tesi F, Bardini G, Ognibene A, Petracca MG, Ciani S, Pezzatini A, Brogi M, Dicembrini I, Cremasco F et al. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes. Diabetes, Nutrition & Metabolism 2004 17 336-342.
29. Johnson N. Metformin is a reasonable first-line treatment option for non-obese women with infertility related to anovulatory polycystic ovary syndrome - a meta-analysis of randomized trials. Australian & New Zealand Journal of Obstetrics & Gynaecology 2011 51 125-129. (doi:10.1111/j.1479- 828X.2010.01274.x)
30. Ouchi N, Higuchi A, Ohashi K, Oshima Y, Gokce N, Shibata R, Akasaki Y, Shimono A & Walsh K. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science 2010 329 454-457. (doi:10.1126/ science.1188280)
31. Hu W, Li L, Yang M, Luo X, Ran W, Liu D, Xiong Z, Liu H & Yang G. Circulating Sfrp5 is a signature of obesity-relatedmetabolic disorders and is regulated by glucose and liraglutide in humans. Journal of Clinical Endocrinology and Metabolism 2013 98 290-298. (doi:10.1210/jc.2012-2466)
32. Legro RS. Obesity and PCOS: implications for diagnosis and treatment. Seminars in Reproductive Medicine 2012 30 496-506. (doi:10.1055/s-0032-1328878)